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Abstract
Background: Clinically, locoregional recurrences following mucinous tumor resection are often experienced.
However, it remains unclear whether mucinous tumors directly affect local recurrence or not, and if so, the
mechanism is not known. Therefore, we investigated whether mucinous tumors are associated with locoregional
recurrence after pulmonary resection and whether mucus extension is a risk factor for locoregional recurrence.
Methods: The data of 152 patients who underwent pulmonary resection for metastases were reviewed. When
mucus was partially or wholly present in the tumor based on macro- or microscopic identification, we assigned the
tumor as mucinous. In mucinous tumors, when mucus was identified within the air spaces in the normal lung
parenchyma, beyond the edge of the tumor, we assigned the tumor as positive for “mucus extension.”
Results: The 5-year cumulative incidence of locoregional recurrence in patients with mucinous tumors was 48.1%,
which was significantly higher than that observed in those with non-mucinous tumors (14.9%). Within the
mucinous tumor, the presence of mucus extension beyond the tumor edge was an independent risk factor for
locoregional recurrence after pulmonary resection (hazard ratio, 5.52; P = 0.019).
Conclusions: During the resection of mucinous cancer, surgeons should maintain sufficient distance from the
tumor edge to prevent locoregional recurrences.
Keywords: Pulmonary resection, Locoregional recurrence, Mucinous tumor, Mucus extension
Background
Despite the developments in chemo- and radiotherapy,
and treatment with biological agents for patients with
pulmonary metastases, surgery remains an important
treatment option [1]. Locoregional recurrences following
lung resection for metastases are often associated with
specific clinicopathological features, such as limited resection,
large tumor size, histologic type, and tumor spread through
air spaces (STAS) [2–5]. Furthermore, these features are
associated with locoregional recurrences and poor prognosis
[3, 4]. Mucinous tumors mainly originate from gastrointes-
tinal cancer [6, 7], pseudomyxoma peritonei [8], lung cancer
[9], pancreatic cancer [10], uterine cancer [11], ovarian
cancer [12], or kidney cancer [13], and sometimes from head
and neck cancer [14]. Some mucinous tumors also have poor
prognosis following surgery [6, 7, 9, 12].
Clinically, in our hospital, we often observe locoregio-
nal recurrences after macroscopic complete resection of
mucinous tumors. In addition, we have noticed that
mucus derived from the tumor often extends through
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air spaces into the lung parenchyma adjacent to the
tumor edge. We have named this phenomenon “mucus
extension.” Mucus extension may be important because
tumor cells can spread through mucus-mediated exten-
sion [8], as shown in Fig. 1. However, it remains unclear
whether this histology could develop tumor recurrence
following pulmonary resection or not. Therefore, using
the data of a cohort of patients with resected pulmonary
metastases, we investigated whether mucinous cancer is
associated with locoregional recurrence following
pulmonary resection and whether mucus extension is a




The institutional review board of the Kusatsu General
Hospital approved our study (Chairman: Sueyoshi Moritani;
Number: 2019–015). The requirement for informed patient
consent was waived because of the retrospective nature of
the study. All methods were performed in accordance with
the journal’s guidelines.
The present study was a retrospective analysis of the
medical records of 152 patients who underwent pulmon-
ary resection for metastases at our hospitals between
September 2007 and December 2019. The inclusion
criteria for patients who underwent surgery were as
follows: 1) the primary tumor was controlled and 2)
there was no effective therapy other than surgery. We
defined the primary tumor as “controlled” when the
tumor had been surgically resected and there were
no recurrences at the time of pulmonary resection.
Furthermore, we enrolled patients whose pulmonary
metastases could have been macroscopically resected.
The medical record of each patient was reviewed for
age, sex, primary tumor, tumor size, number of pulmonary
lesions, regions of pulmonary nodules, the surgical proced-
ure for the metastasectomy, and postoperative chemother-
apy. We performed wedge resection for metastatic lesions,
using an automated suturing device (Endo GIA tri-stapler,
Covidien or Endopath stapler Echeron flex, Ethicon,
Cincinnati, OH). During the resection, we decided to cut
the lung at approximately 1 cm from the tumor edge. We
selected segmentectomy, lobectomy, or pneumonectomy
when the tumors were located in the hilum or when
multiple nodules were present in the same lobe. Lymph
node dissection was not routinely performed. Following
metastasectomy, the patients were followed-up for a
maximum of 5 years. All recurrences were confirmed by
radiological assessment. Locoregional recurrence was
defined as a nodule occurring on the resection stump of
the lung or bronchus and the nodule expanding during
follow-up computed tomography examinations.
We classified patients into the mucinous and non-
mucinous tumor groups. If mucus was partially or wholly
present in the tumor based on macro- or microscopic
identification, we assigned the tumor as mucinous. We
analyzed the recurrence-free survival and the cumulative
incidence of locoregional recurrence in the mucinous
tumor group, and compared these values with those of the
control (non-mucinous tumor group). If there were mul-
tiple lesions in a single patient, we judged that recurrence
had occurred in cases where at least one lesion recurred.
Furthermore, in the mucinous tumor group, the primary
Fig. 1 The tumor cells (arrows) exist in the mucus
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tumor, tumor size, regions of pulmonary nodules, surgical
procedure, postoperative chemotherapy, and presence of
mucus extension were recorded.
Histologic evaluation
The surgically resected specimens were fixed by injecting
10% formalin slowly into lung parenchyma by 23-gauge
needle. The fixed specimens were cut into 5–10mm
slices with only one stroke using a new knife. All sec-
tions that contained a tumor tissue and a surrounding
normal lung tissue were embedded in paraffin. Add-
itional 5-μm sections were cut from a selected tissue
block and stained with hematoxylin and eosin.
We microscopically examined the edge of the tumor
or mucus. Specimen sections were divided into two
groups: those where the border between the tumor and
normal lung tissue was clear (Fig. 2a, b) and those where
the border was not clear (Fig. 2c, d). In the former
group, the tumor edge was identified as a smooth
surface easily recognizable at gross or low-power field
examination, as indicated by the dotted line in Fig. 2a
and b. In the latter group, we found mucus in the nor-
mal alveoli. To distinguish the mucus in the normal al-
veoli from the mucus in the tumor, we performed the
following procedure: First, we observed the size of nor-
mal alveoli apart from the tumor cells or mucus. When
the mucus existed in the normal size alveoli, we judged
the mucus spreading to normal alveoli. When alveoli
sizes were expanded or alveolar structure was destroyed
by the mucus, we judged it as the mucus within the
tumor (indicated by arrows in Fig. 2c, d). We named this
phenomenon “mucus extension.” The above pathological
diagnoses were performed by YK, and one expert path-
ologist (MI) checked the diagnoses.
Statistical analysis
Statistical analysis was performed using SPSS Statistics
for Windows, version 25 (IBM Corp., Armonk, NY). As-
sociations between variables were analyzed using Fisher’s
exact test (for categorical variables) and the Wilcoxon
test (for continuous variables). The Kaplan–Meier
method was used to determine the overall survival,
relapse-free survival, and cumulative incidence of locore-
gional recurrence (CIR). The log-rank test was used to
compare survival differences for each variable. Cox’s
proportional hazards model was used for multivariate
analysis. Statistically significant differences were defined
as P < 0.05.
Results
Survival comparison between mucinous and non-
mucinous tumors
To examine the association between mucinous tumors
and locoregional recurrence, we compared recurrence-
Fig. 2 (a, b) The border between the tumor/mucus and the normal lung tissue is clear. A border is identified as an easily recognizable smooth
surface, indicated by a dotted line. (c, d) The border between the tumor/mucus and normal lung tissue is not clear. Mucus is identified within air
spaces in the normal lung parenchyma beyond the edge of the tumor (arrows)
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free survival between patients with and without mucin-
ous tumors who underwent pulmonary resection for me-
tastases. The characteristics of both groups are
presented in Table 1. In total, 38 patients were diag-
nosed with a mucinous tumor, where the primary tu-
mors were originated from gastrointestinal cancer (26
patients), pseudomyxoma peritonei (10 patients), lung
cancer (one patient), and urinary tract cancer (one pa-
tient). Moreover, 114 patients were diagnosed with a
non-mucinous tumor, where the primary tumors were
originated from gastrointestinal cancer (73 patients), kid-
ney/urinary tract cancer (16 patients), head and neck
cancer (12 patients), uterine cancer (six patients), lung
cancer (one patient), and cancer in other sites (six pa-
tients). In gastrointestinal cancers, which were most mu-
cinous tumors, intestinal (Hazard Ratio [HR], 0.98) and
pancreatic cancer (HR, 12.0) have a risk of presenting a
mucinous tumor (Table 2). The pathological types of tu-
mors, including the number of patients and the number
of metastatic lesions, are presented in Table 3. The mu-
cinous tumors comprised adenocarcinoma in 37 patients
(97%) and urothelial carcinoma in one patient (3%). The
non-mucinous tumors comprised adenocarcinoma,
squamous cell carcinoma, clear cell carcinoma, urothelial
carcinoma, and other types in 84 (74%), seven (6%), 12
(11%), four (4%), and seven patients (6%), respectively.
The recurrence-free survival rate after pulmonary resec-
tion in the patients with mucinous tumors was 11.3%,
which was significantly lower than that observed in pa-
tients with non-mucinous tumors (31.2%; Fig. 3). We
suspected that this low recurrence-free survival rate in
patients with mucinous tumors was mainly the result of
locoregional recurrences. Therefore, we examined the
CIR rate and found that the 5-year CIR rate in patients
with mucinous tumors was 48.1%, which was signifi-
cantly higher than that observed in patients with non-
mucinous tumors (14.9%; Fig. 4).
Association between locoregional recurrence and mucus
extension
We suspected that locoregional recurrence would easily
occur in mucinous tumors via mucus-mediated exten-
sion. We identified 70 metastatic lesions in 38 patients
with mucinous tumors, and 13 lesions developed locore-
gional recurrences. In contrast, we identified 179 meta-
static lesions in 114 patients with non-mucinous tumors,
while in 14 lesions, locoregional recurrences were devel-
oped. Of the 70 lesions in mucinous tumors, we identi-
fied 35 (50%) with mucus extension present. We
extracted the potential risk factors of locoregional
Table 1 Characteristics of patients with mucinous and non-mucinous tumors
Variables Mucinous Non-mucinous P value
N = 38 % N = 114 %
Age, years
Median 61.3 – 64.3 – 0.579
Range 33–77 29–90
Gender
Male 23 26 65 74 0.450
Female 15 23 49 77
Primary tumor
Gastrointestinal cancer 26 26 73 74 0.565
Pseudomyxoma peritonei 10 100 0 0 < 0.001
Lung cancer 1 50 1 50 0.355
Kidney, urinary tract cancer 1 6 16 94 0.026
Head and neck cancer 0 0 12 100 0.050
Uterus cancer 0 0 6 100 0.174
The others 0 0 6 100 0.174
Surgical procedure
Partial resection/ enucleation 31 24 97 76 0.271
Segmentectomy 7 29 17 71 0.492
Lobectomy 7 40 9 60 0.224
Postoperative chemotherapy
(+) 16 26 45 74 0.396
(−) 17 20 67 80
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recurrence as follows: histological type, maximum tumor
size, central region of the tumor (tumor existing partially
or wholly inside one-third of the area of a pulmonary
pleura), postoperative chemotherapy absent, and limited
resection (enucleation, wedge resection, or segmentect-
omy). Associations between these risk factors and mucus
extension are analyzed and summarized in Table 4. The
risk of developing locoregional recurrence was higher in
patients with a maximum tumor size ≥20mm, tumors in
the central region, postoperative chemotherapy absent,
and mucus extension. In multivariate analysis, the pres-
ence of mucus extension was the independent risk factor
for locoregional recurrence (HR, 5.52; P = 0.019)
(Table 5).
In gastrointestinal mucinous tumors, mucus extension
was more frequently observed in pancreatic (HR, 2.54)
and intestinal cancers (HR, 0.92) (Table 6).
Limited resection of mucinous tumors and locoregional
recurrence
We considered that limited resection may increase the
risk of locoregional recurrence. Of 70 lesions, seven and
63 were resected using lobectomy and limited resection
(enucleation, wedge resection, and segmentectomy;
Table 2 Multivariate analysis of presence or absence of mucus in the gastrointestinal cancers
Variables Mucinous Non-mucinous HR 95% CI P value
N = 26 % N = 73 %
Gastrointestinal cancer
Intestinal cancer 19 22 66 78 0.98 0.43–2.24 0.968
Gastric cancer 0 0 2 100 0.00 – 0.999
Pancreatic cancer 7 78 2 22 12.0 2.20–65.3 0.004
Liver cancer 0 0 3 100 0.00 – 0.999
Table 3 The pathological types of tumors, and the number of patients and metastatic lesions
Variables Mucinous Non-mucinous
Patients Lesions Patients Lesions
Total 38 70 114 179
Gastrointestinal cancer 26 47 73 112
adenocarcinoma 26 47 70 105
hepatocellular carcinoma 0 0 3 7
Pseudomyxoma peritonei 10 21 0 0
adenocarcinoma 10 21 0 0
Lung cancer 1 1 1 1
adenocarcinoma 1 1 0 0
squamous cell carcinoma 0 0 1 1
Kidney, urinary tract cancer 1 1 16 23
clear cell carcinoma 0 0 12 18
urothelial carcinoma 1 1 4 5
Head and neck cancer 0 0 12 24
papillary adenocarcinoma 0 0 8 20
squamous cell carcinoma 0 0 4 4
Uterus cancer 0 0 6 12
leiomyosarcoma 0 0 3 8
adenocarcinoma 0 0 2 2
squamous cell carcinoma 0 0 1 2
The others 0 0 6 7
adenocarcinoma 0 0 4 5
adenosquamous cell carcinoma 0 0 1 1
squamous cell carcinoma 0 0 1 1
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Fig. 3 Recurrence-free survival after pulmonary resection in patients with mucinous tumors is 11.3%, which is significantly lower than that
observed in patients with non-mucinous tumors (31.2%)
Fig. 4 The 5-year CIR rate in patients with mucinous tumors is 48.1%, which is significantly higher than that observed in patients with non-
mucinous tumors (14.9%). CIR, cumulative incidence of locoregional recurrence
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Table 4), respectively. There was no locoregional recur-
rence in lesions resected using lobectomy. However, in
13 lesions (20.6%) where limited resection was applied,
locoregional recurrence was developed (Fig. 5).
Discussion
The purpose of this study was to clarify whether mucin-
ous tumors are associated with locoregional recurrence
after pulmonary resection and establish whether mucus
extension is a risk factor for locoregional recurrence ac-
cording to the surgical procedure type.
Previously, STAS was not accepted as a form of
invasion because it is unique to the lungs. Anatomically,
the lungs have air pathways, which permit tumor cells to
spread. Kadota et al. identified STAS in 40% of lung
adenocarcinoma cases and found that locoregional recur-
rence after pulmonary resection significantly increased in
STAS-positive tumors [2]. Shiono et al. also demonstrated
that aerogenous spread with floating cancer cell clusters
was an independent prognostic factor [4]; moreover, float-
ing cancer cell clusters and a malignant positive surgical
margin in the resected specimens carry significantly higher
risk for local recurrence [5] in cases of colorectal pulmon-
ary metastasis. Based on these reports, STAS is coming to
be recognized as a pattern of invasion. Previously, we
showed that mucinous tumors can spread through
mucus-mediated extension [8] in a manner resembling
dissemination. Therefore, we hypothesized that the mucus
could easily spread through air spaces and that it might be
possible for cancer cells to extend via the mucus, resulting
in local recurrence. Here, we demonstrated that the
recurrence-free survival rate after pulmonary resection in
patients with mucinous tumors was significantly lower
than that in patients with non-mucinous tumors. This re-
sult was similar to those of reports on mucinous tumors
found in other parts of the body, which were also associ-
ated with high recurrence rates [6, 7, 9, 12].
We considered that mucus extension could be a sensi-
tive marker of locoregional recurrence similar to STAS.
We found mucus extension, identified microscopically
based on the lack of a distinct border between the tumor
and the normal lung tissue, to be present in 50% of
mucinous tumors. We considered that mucus extension
might cause tumor spread in these cases and, therefore,
we hypothesized that mucus extension might be a risk
factor for locoregional recurrence. Thus, we extracted
the risk factors for locoregional recurrence using the 3-
Table 4 Clinicopathological associations with locoregional recurrence in mucinous tumors
Variables in mucinous tumor Lesions % 3-year CIR (%) P value
All lesions 70 – 35.5 –
Gastrointestinal cancer 47 67 30.7 0.756
Pseudomyxoma peritonei 21 30 Not reached 0.557
The others 2 3 Not reached 0.497
Maximum tumor size
< 20mm 55 79 26.9 0.460
≧20 mm 15 21 57.1
Region of the tumor
Central 29 41 48.7 0.180
Peripheral 41 59 15.2
Surgical procedure
Enucleation, wedge, segmentectomy 63 90 40.5 0.156
Lobectomy 7 10 0.0
Postoperative chemotherapy
(+) 32 62 27.4 0.663
(−) 20 38 42.1
Mucus extension
(+) 35 50 55.1 0.013
(−) 35 50 8.7
Table 5 Multivariate analysis of locoregional recurrence in
mucinous tumors
Variables HR 95% CI P value
Maximum tumor size≧20mm 1.94 0.56–6.77 0.297
Region of the tumor: Central 2.01 0.55–57.43 0.293
Postoperative chemotherapy (−) 0.81 0.26–2.54 0.717
Mucus extension: (+) 5.52 1.37–31.2 0.019
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year CIR rate, which identified the factors as follows:
maximum tumor size ≥20mm, tumors in the central
region, postoperative chemotherapy absent and mucus
extension (univariate analysis). In multivariate analysis,
we found that mucus extension was the key independent
risk factor for locoregional recurrence following pul-
monary resection.
Surgeons need to select the optimal surgical procedure
for complete resection of lung tumor. Tumor STAS can
be difficult to recognize on the frozen section because
STAS tumor cells and alveolar macrophages have similar
morphologies. When distinction is difficult, immunohis-
tochemistry for keratin and a macrophage marker, such
as CD68, may be needed [2]. Conversely, mucus exten-
sion could be identified using a frozen section during
the operation. In this study, we showed that locoregional
recurrence occurred in patients who underwent enucle-
ation, wedge resection, and segmentectomy, but did not
occur in those who underwent lobectomy, suggesting
that limited resection may increase the risk of locoregio-
nal recurrence. Therefore, in the future, in cases where
mucus extension can be identified during the operation,
this may help surgeons decide on the need for additional
resection or anatomical lung resection. In this study,
locoregional recurrence occurred in cases of mucinous
tumors with 1-cm resection margins; therefore, margins
> 1 cm from the tumor edge should be selected to avoid
recurrence.
The main limitation of this study was the heterogen-
eity of the primary tumor histology. We resected the
metastatic tumors irrespective of their primary histology
because a recent report showed the effectiveness of
pulmonary metastasectomy [15]. However, tumor char-
acteristics, such as growth speed, invasive capacity, and
metastatic potential, may differ according to mucus
existence and the histology of the primary lesion. In
Table 6 Multivariate analysis of mucus extension in gastrointestinal cancers
Mucus extension (+) (−) HR 95% CI P value
Lesions % Lesions %
Gastrointestinal cancer
Intestinal cancer 17 46 20 54 0.92 0.33–2.63 0.887
Pancreatic cancer 7 70 3 30 2.54 0.52–12.4 0.247
Fig. 5 The locoregional recurrence rates were 20.6% for enucleation, wedge resection, or segmentectomy, and 0% for lobectomy
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particular, there was histological variability between pa-
tients with mucinous and non-mucinous tumors, which
might have affected the recurrence-free survival. A
second limitation was the small number of cases, which
did not provide sufficient power to detect significant
differences; therefore, the statistical analysis results may
be questionable. Third, we may have underestimated the
mucus extension. We observed only the maximum
surface of the tumor, and the other surfaces may have
potentially contained mucus extension. Fourth, we
cannot avoid the possibility of artificial mucus extension.
When the lung was resected with automated suturing
device or the specimens were injected of formalin, or cut
with knife, mucus extension might have been developed
artificially by compression. Finally, the diagnosis of local
recurrence was equivocal. We confirmed locoregional
recurrence through radiological assessment, not by bi-
opsy, which may sometimes misinterpret inflammatory
consolidation as locoregional recurrence.
Based on this original study, we intend to spread
awareness of the potential risk of postoperative locore-
gional recurrence in patients with mucinous tumor and
mucus extension. Furthermore, a large trial targeting
mucinous tumor resection is required to achieve more
precise results in the future.
Conclusions
We demonstrated that mucus extension may be a risk
factor for locoregional recurrence after pulmonary resec-
tion for lung metastases. Apart from the histology of the
primary tumor, whether the tumor is mucinous or non-
mucinous should also be considered when pulmonary
resection is planned. In the future, we hope that mucus
extension can be identified using frozen sections during
surgery and that surgeons will consider additional resec-
tion to maintain sufficient distance from the tumor edge
and prevent locoregional recurrences.
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